Larry D. Lynd

Scientist, PhD, BSP

Dr. Larry Lynd is a Professor in the University of British Columbia (UBC) Faculty of Pharmaceutical Sciences and is the Director of the Collaboration for Outcomes Research and Evaluation.

Research Interests

  • Pharmacoeconomics
  • Pharmacoepidemiology
  • Health services research
  • Asthma
  • Risk-benefit analysis
  • Health economics
  • Outcomes research
  • Longitudinal analysis
  • Toxicology
  • Population health

Additionally, he is an Associate of the UBC School of Population and Public Health, and a Scholar at the Peter Wall Institute for Advanced Studies at UBC.

Read Less Read More

Formerly, he was a Michael Smith Foundation for Health Research Scholar and a Canadian Institutes of Health Research (CIHR) New Investigator.

Dr. Lynd has more than 200 peer-reviewed publications, book chapters, and research abstracts. Recently, he was appointed as the Chair of the Health Canada Special Advisory Committee on Nonprescription Drugs, and to the Special Advisory Committee to the Respiratory and Allergy Therapies Division of Health Canada, and he sits as the economics expert on the B.C. Ministry of Health Services Expensive Drugs for Rare Diseases Committee. His primary research interests are in the areas of risk-benefit analysis, pharmacoepidemiology, health economics, and policymaking for drugs for rare diseases. He is the principal investigator on the CIHR New Emerging Team for Rare Diseases, focused on policy and decision-making for orphan drugs. Projects include Million Dollar Meds.